Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CStone Approved to Start China Clinical Trials of PD-1 Candidate

publication date: Jul 12, 2018

Suzhou CStone Pharma reported the China National Drug Administration (CNDA) has approved the first clinical trial application in China for CStone's PD-1 mAb, CS1003. CStone said the CNDA reviewed its filing under new rules, issuing a decision in just four months, dramatic proof of the agency's modernization of clinical trial approvals. CStone plans to start a multi-center China Phase I trial in patients with advanced cancers. CStone positioned CS1003 as a key part of the company's plan to develop combination immuno-therapy regimes for cancer. It is also developing a PD-L1 candidate. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
ChinaBio Partnering Forum 2019
Shanghai , China
May 8-9, 2019
 
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events